Dyne Therapeutics Receives FDA Fast Track Designation For DYNE-251 For The Treatment Of Duchenne Muscular Dystrophy
Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the